Ludwig Enterprises, Inc. announced that the company has received Continuing Review Approval on its planned clinical study from Advarra IRB, Columbia, MD. Ludwig clinical study LL301 is titled: "Using Measurements of mRNA and Elisa- based Cytokine/Protein Indices to Evaluate Pre- and Post-Diagnosis and Treatment Response of Patients with Urothelial Carcinoma of the Bladder".
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.22 USD | +0.92% | 0.00% | +62.36% |
- Stock Market
- Equities
- LUDG Stock
- News Ludwig Enterprises, Inc.
- Ludus Enterprises, Inc. Receives Continuing Review Approval on Planned Clinical Study from Advarra IRB, Columbia, MD